Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Egetis Therapeutics, Audiocast, Q2'26

By Inderes8/21/2026, 12:00 PM
Egetis Therapeutics

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Nicklas Westerholm
00:01 - 04:00

Thank you. Operator. Good afternoon. Good morning, and a warm welcome to the Egetis Therapeutics second quarter results webcast, which is planned for the coming 30 minutes. For those whom I haven't had the privilege to meet before, my name is Nicklas Westerholm, and I am the CEO of the company. I will start today's session with a short business update. This will be followed by Anny Bedard, President of our U.S. And North American business, who will discuss the launch preparations for the planned Emcitate launch in the US, subject to approval. Then, Henrik Krook, Vice President, Commercial Operations, will give a commercialization update of Emcitate in the European Union, as well as other international markets. Finally, Yilmaz Mahshid, Chief Financial Officer, will provide a financial update before we look ahead to the exciting upcoming key value-enhancing milestones; we aim to leave ample time for Q&A at the end of the session. The most significant event during the first half of 2026 was the acceptance of our US New Drug Application, NDA, for Emcitate. The grant of a priority review by the FDA with a PDUFA date set for the 28th of September. So far, it has been a collaborative dialogue with the agency throughout the review. The FDA has confirmed that it expects to finish its review by the PDUFA date on the 28th of September, and does not plan to hold an advisory committee meeting, subject to approval. The Emcitate launch in the US is planned for the fourth quarter of this year. We were also granted our first patent for Emcitate by the US Patent and Trademark Office. The patent provides protection for a novel composition with tiratricol as the active ingredient. The claims cover, amongst other things, a method of treatment for MCT8 deficiency with the claimed pharmaceutical composition that encompasses tiratricol dosing regimens and tiratricol compositions with specific excipients. This patent is a significant milestone in strengthening our intellectual property portfolio. We expect the granted patent to be Orange Book listed with an expiration date of 2045. Revenue for the second quarter was 17.4 million MSEK, corresponding to year-on-year growth of 23% at a constant exchange rate. As Henrik will describe further, the Emcitate price negotiations within the German reimbursement process, AMNOG, were successfully concluded in the second quarter. Furthermore, in the quarter, we also successfully carried out a substantially oversubscribed directed share issue amounting to 350 million Swedish kronor, approximately 38 million USD at the closing price on Nasdaq Stockholm on the day of the raise. We were particularly pleased to see strong participation from both existing shareholders and several new international specialist healthcare investors, which will further broaden our shareholder base. Last but not least, we are pleased to welcome Tiago Nunes, a very seasoned drug developer, as our new Chief Medical Officer in May. One of Tiago's main tasks will be to drive Emcitate's exciting indication expansion opportunity in resistance to thyroid hormone beta forward in the short-term future. I will now hand over to Anny. Anny, please go ahead.

Anny Bedard
04:00 - 08:08

Thank you, Nicklas. Good afternoon and good morning, everyone. We're approaching an exciting milestone, one that could bring the first approved therapy to a community that has waited a long time for it. With fewer than 30 business days to the PDUFA date, our focus is now on disciplined execution to enable a US launch in Q4. Since our Q1 update, we've completed the build-out of our US commercial organization. Our medical affairs and field teams are fully trained and deployed, and an experienced team of rare disease professionals is now executing a single integrated launch plan. The organization is just over 20 employees today, supplemented by specialized consultants, and will scale to around 25 at launch. Launch readiness activities are advancing across all critical workstreams depicted on this slide. The Patient Support Services operating model has been established. Payer engagements and value communication activities are underway, and specialty distribution and supply partners have been contracted. We continue to expand engagement with the specialist physicians most likely to diagnose and treat MCT8 deficiency. These are the pediatric endocrinologists, pediatric neurologists, and geneticists. We are also expanding patient identification efforts to increase diagnosis and support long-term market development. Our continued engagement with patient advocacy organizations helps increase disease awareness, support patient identification efforts, and inform our understanding of community needs. Our top priority at launch will be continuity of care for patients currently receiving Emcitate through the Expanded Access Program. Ensuring a seamless transition to commercial supply reduces the risk of treatment interruption and supports initial commercial adoption. Today, approximately 60 patients across 17 sites nationwide are being treated under the Expanded Access Program, a number that continues to grow month over month. We are prepared to support each patient's transition across the key touchpoints by confirming the treating physicians, enabling prescriptions, and coordinating access support. This includes prescriber and caregiver education ahead of approval, along with affordability programs and bridging support designed to keep treatment access uninterrupted throughout the transition. We are also establishing coordination across physicians, the specialty pharmacy, patient services, and payers so any potential barrier can be identified and resolved quickly. In parallel, we will continue to engage known patients not yet on therapy while expanding diagnosis and patient identification, with the organization built, the infrastructure being activated, and patient transition plans advancing. We believe the US business is positioned to execute at approval and deliver on a successful launch in Q4. Most importantly, we're doing this for a patient community that has had no approved therapy options to date, and we're really energized by the opportunity to change that. Thank you. I will now turn it over to Henrik for an update on commercialization in Europe and international markets.

Nicklas Westerholm
08:09 - 11:48

Thank you, Anny, for Europe and other international markets. Q2 was another quarter of progress for Emcitate with continued revenue growth. The conclusion of the German reimbursement process and further expansion of access beyond our initial launch market. Revenue in Q2 was 17.4 million SEK, with Germany as the largest contributor. This corresponds to 23% growth at constant exchange rates compared with Q2 last year and approximately 30% sequential growth compared with Q1. In Germany, the AMNOG price negotiations with GKV-Spitzenverband were concluded during the quarter. We are pleased that the German authorities recognized the value of Emcitate. The new negotiated price and further insights into daily dosing lead to an estimated average annual treatment cost just below €200,000. This is an important step while we continue our field-based work with pediatric endocrinologists, pediatric neurologists, other specialist physicians, and relevant treatment centers to develop the German market further. And here I would like to make a clarification because, once we... This analyst has misunderstood how sales revenue is accounted for in Germany; in May 2025, we started commercial sales based on an initial price in line with how the German system works, which are then reported. Sales have reflected the final negotiated price based on our assumptions, meaning that all our reported sales revenue since November 2025 accounts for the final negotiated price. Beyond Germany, we are progressing toward reimbursed access in additional European countries. In Spain, the National Pricing and Reimbursement dossier has been submitted, as it has in Italy and France. We plan to strengthen the value dossiers with Emcitate survival data once it has been published in the peer-reviewed journal. At the same time, we continue to use funded access routes where available in other European countries, helping treatment reach patients through the most appropriate access pathway in each country internationally. We also see growing reach through our distribution partners. We are supported by Er-Kim in Turkey, plus Central, Eastern and Southeastern Europe, and by Taiba Rare in the Gulf region. Both Er-Kim and Taiba Rare are actively identifying patients and initiating the processes, aiming for funded treatment, which contributed to named patient sales revenues in Poland and Turkey in the quarter. We also signed a collaboration and supply agreement with Orspec Pharma for Australia and New Zealand, further broadening the geographic reach for Emcitate. So, taken together, this reflects solid commercial progress. Germany now has an agreed reimbursed price. We are advancing funded pathways in key European countries and a partner model is helping us reach patients in additional geographies. With that, I would like to hand over to our CFO, Yilmaz Mahshid.

Yilmaz Mahshid
11:50 - 15:08

Thank you, Henrik. To start with, all numbers, unless called out, are in our reporting currency, Swedish kronor. Revenue for the first three months was 17.4 million MSEK versus 14.5 million MSEK in the same period last year, corresponding to a year-over-year growth of 23% in constant exchange rates. The gross profit is 3.6 MSEK. This comes back to the continued depreciation of balance sheet R&D and non-cash items, excluding the quarterly depreciation of 10.1 MSEK. Gross profit would have been 13.7 million SEK, corresponding to an adjusted gross margin of approximately 79%, which is considerably stronger than the 74% in the last quarter. As long as we are in an initial ramp-up phase in Europe, the depreciation will have a meaningful impact on the reported gross margin. However, we anticipate this to gradually dissipate as we start rolling out Emcitate in the US post a potential FDA approval. Q2 2026 operating results were -109.3 MSEK versus -78.5 MSEK in the prior period. I just want to highlight that 5.6 MSEK of the administrative costs are booked in the quarter. Our employee stock option plan related bookings are non-cash items. This is a year-over-year delta of 12.5 MSEK, as the Q2 2025 numbers included a positive booking of 6.9 MSEK. Also, a one-time cost of approximately 4 million MSEK was booked during this quarter for social charges in connection with the ESOP exercise. These numbers should help you understand the underlying administrative cost line item during the quarter. Overall, the lower results are due to our continued investments and the work with the US FDA, US commercial and corresponding pre-launch activities. The management, the board, and our main shareholders are all aligned that investing in the US is a key priority, as we believe this will be by far our most important market and where we need to succeed. For the second quarter, cash flow from operating activities was -93.9 million versus -59 million, as highlighted in the report. We strengthened the cash position further on April 21st. In total, we raised 350 million SEK, corresponding to approximately 38 million USD on a gross basis. The high demand for the shares offered was depicted by the fact that they were issued at a share price of 5.25 SEK, which corresponds to a 0% discount to the market close the same day with the cash from this transaction. We ended the quarter with a healthy cash position of 378 MSEK, corresponding to approximately 40 million USD. With that, I would like to hand back to Nicklas.

Nicklas Westerholm
15:10 - 17:12

Thank you, Yilmaz. Let me summarize. And whilst reflecting on the first two quarters of 2026, it is clear that we have made significant progress. I am very proud to say that we have had several key deliverables that have been met with a very successful outcome. Let me also remind you of the upcoming milestones from Egetis Therapeutics. We have a PDUFA date set for the 28th of September. Subsequently, subject to approval, we expect to launch Emcitate in the US in quarter four. As our most important market, it is also worth noting that we expect to be granted a Priority Review Voucher upon approval. It is likely that monetization of such a Priority Review Voucher could take place in the fourth quarter. Of note is that PRVs sold in 2026 have fetched between 180 and 220 million USD each. Last but not least, is the preparation for indication expansion into RTH-beta. Our next exciting pipeline opportunity is now progressing at pace. We are convening a scientific advisory board with key opinion leaders in the field to finalize the development program for Emcitate in RTH-beta and are in parallel preparing for regulatory interactions to agree the overall development pathway with the aim of starting a clinical study during 2027. Of note is that we have today over 50 patients with RTH-beta that are being treated with Emcitate as a part of a managed access program. In summary, we believe that the commercial opportunity here could be on par with the one for MCT8 deficiency. With that, I'll hand over to the operator for Q&A. Thank you.

Operator
17:13 - 17:31

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Kristen Kluska from Cantor Fitzgerald. Please go ahead.

Kristen Kluska
17:33 - 17:54

Hi. Good afternoon, everybody, and congrats on all of the progress over this last quarter. While respecting you are still very much in active review with the FDA. Can you give us any high-level feedback on the mid-to-late-cycle meeting? Was there anything substantial that came up? Anything that surprised you, for example?

Nicklas Westerholm
17:56 - 18:52

Thank you, Kristen, and great to hear from you. Well, in essence, we as always, do not communicate around ongoing regulatory interactions. Having said that, though, to give some more color, as mentioned during the call, it has been a very constructive and productive dialogue with the FDA. The FDA has also reiterated that they will hold true to the PDUFA date set on the 28th of September. They are not planning to hold an advisory committee. And of course, with respect to that, if something would have materially deviated from our internal plans, i.e. A date on the 28th that would have been seen as material would subsequently require us to notify the market. So I think all in all, internally we are very pleased with the dialogues with the agency so far and looking forward to the PDUFA date on the 28th.

Kristen Kluska
18:54 - 19:26

Okay. I appreciate those comments. Thank you. And then on the survival data, I know we could expect this perhaps in a peer-reviewed journal at some point, but can you just remind us, has the FDA reviewed these data yet? I understand you cannot comment on all of the findings while we wait for the peer-reviewed journal publication. But again, at a high level, what do those data perhaps include that have not been reported? Again, without getting into the specifics of findings. Thank you very much.

Nicklas Westerholm
19:26 - 20:12

Thank you, Kristen. And again here, I fully appreciate your question. I cannot provide much more granularity on that. Unfortunately, the data, as you mentioned, has not yet been published in a peer-reviewed journal. But as mentioned previously, both during calls like this and through reports, if you think about the New Drug Application that was submitted, it included data from numerous clinical trials. Trial. Trial one. Trial. Trial two, the retrial study, and also the survival study. And of course, as that was part of the submission package, the FDA has reviewed and examined the different studies to provide a view on the benefit-risk profile of the drug.

Kristen Kluska
20:17 - 20:18

Thank you so much.

Nicklas Westerholm
20:19 - 20:20

Thank you. Kristen.

Operator
20:25 - 20:30

The next question comes from Chiara Montironi from Van Lanschot Kempen. Please go ahead.

Chiara Montironi
20:32 - 20:55

Hello, Henrik. Thanks for taking my question and congratulations on the progress. So you now disclose that 60 patients are treated in the Early Access Program versus 40 at the beginning of the year. I was wondering whether the new 20 patients are previously identified patients or if these are completely new diagnoses.

Nicklas Westerholm
20:56 - 21:22

So thank you. And you are absolutely right. And thank you for your question. By the way, as I mentioned at the start of the year, we had roughly or approximately 40 patients on the EAP program. So the progress here has been very good. We have now around 60 patients, as Anny mentioned, enrolled. We don't give the granularity if these are patients newly identified or previously identified, but I will invite Anny to comment further, if any.

Anny Bedard
21:23 - 22:07

Yes, thank you. We. We have 17 sites across the country that are engaged in treating these patients, pre-approval. And of course, these are now serving as reference sites for other physicians who identify patients. So having those physicians with experience in treating these patients and with tiratricol is significantly raising awareness among other physicians in the community. So that has been a contributor to having more patients wanting and requesting to join this program.

Chiara Montironi
22:09 - 22:29

Thank you. I appreciate the color. And if I may, a follow-up question. So if Emcitate were to be approved in September, how long will it take to convert the Expanded Access Program patients to the commercial product? And which elements could delay the transition in your opinion?

Nicklas Westerholm
22:30 - 23:01

Thank you, Chiara. Of course, a very valid question. I think it is again premature to comment in detail on how long it will take to transition the EAP patients over to commercial patients. Right. This is obviously something the team is working very hard on mapping out the different patient flows throughout the value chain. But I invite Anny to comment somewhat further if you can add some more granularity to this.

Anny Bedard
23:01 - 23:53

Yes. So this will be a main priority for us because we want to make sure that treatment is uninterrupted for those patients. As is standard in rare disease, we will have affordability support and bridge mechanisms in place to safeguard this continuity of care, and as we do that, we will be in close communication with the physicians and with the payers as well. As Nick mentioned, we are not going to go into the detail at this time on the specific number of days for transition, but that will be the core focus of our activities at the time of the launch. We anticipate that this will be successful.

Nicklas Westerholm
23:53 - 24:23

And maybe to build on for the rest of the call, Chiara, that this is a key priority. Just reiterating what Anny said before, it is a key priority for the organization to ensure a very swift, smooth, and coordinated transition from the Expanded Access Program to commercial supply, driven to a certain extent by minimizing treatment disruption, but also to support the earliest commercial uptake once approved. So thank you for the question, Chiara.

Chiara Montironi
24:24 - 24:24

Of course.

Operator
24:31 - 24:35

The next question comes from Clemens Tiara from Stifel. Please go ahead.

Clemens Tiara
24:36 - 25:01

Hi. Thanks for the presentation and thanks for taking my question. Just a bit of focus on Europe might be a candid question, but regarding the price in Germany, you mentioned just below €200,000, right? Can you confirm that this is a negotiated reimbursement price? And obviously, you cannot disclose anything. Do you expect a material difference with the net price? That would be the first question.

Nicklas Westerholm
25:04 - 25:45

Thank you, Clemens. I can start and I might ask Henrik to comment. As we mentioned during the launch process in May 2025. The estimated average annual treatment cost per patient was just above €200,000 per patient per annum, with a new negotiated price and further insights about daily dosing, which is an important component when looking at annual treatment costs. The average annual treatment cost now is estimated to be just below €200,000. We do not share any confidential rebates, etc. But this is based on the lowest price available for pharmacies in Germany.

Clemens Tiara
25:47 - 25:58

Okay, perfect. Thank you. And maybe looking ahead on RTH-beta as you finalize the development plan, can you share some insight? Am I interrupting?

Nicklas Westerholm
25:58 - 26:02

No, not at all. I got so excited about the question. So.

Clemens Tiara
26:05 - 26:19

I was saying, can you say at this stage what an approvable program could look like in terms of number and size of studies, endpoints, and how much of the existing Emcitate clinical and safety package could help streamline that program?

Nicklas Westerholm
26:20 - 27:53

Sure. That is a really good question. I was so excited by you asking that question. Since this is a very important feature of the long-term future of the company in building a sustainable rare disease organization, it is somewhat premature to comment on some of the questions you had there. What we are doing today is that we are in the last stages of finalizing a target product profile and a clinical development plan. As I mentioned, we are convening an advisory board of key opinion leaders, which will be gathering face-to-face around the European Thyroid Association conference in Portugal in September. And subsequent to that, we have an ambition to finalize the design and start engaging with the FDA and EMA on the regulatory pathway. The ambition here is, of course, to utilize as much data as possible from the MCT8 deficiency safety database. We have a huge safety database with a substantial number of years of patient exposure. So that is of course something to be utilized further in the RTH-beta development program. And the same goes for non-clinical studies and the work carried out there ahead of the US approval. And so, with that in mind, it is a bit premature to comment on endpoints, sample size, number of centres, etc. But rest assured, that is something we will update the market on as soon as we have concluded that internally.

Clemens Tiara
27:55 - 27:57

Okay, perfect. Thank you so much.

Nicklas Westerholm
28:00 - 28:09

Thank you. And I think that brings us to the end of the call. We appreciate your participation and wish you a great rest of the day. Thank you.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…